Celgene (CELG -2.5%) slides on a UBS downgrade to Neutral on valuation this morning. The firm...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG -2.5%) slides on a UBS downgrade to Neutral on valuation this morning. The firm cites a lack of significant upside to its anemia drug Revlimid, saying the story has already "played itself out" since approval for the drug was shot down in the European Union.